Table 1 Patients treated with daratumumab reaching a 12-month follow-up

From: Daratumumab monotherapy for refractory lupus nephritis

 

Sex/gendera

Age at the onset (years)

Disease duration (years)

Previous treatments

LN

classb

(A/C)c

Cumulative prednisone dose during the study (mg)

Residual steroid dose at 12 monthsd

Pt 1

M/M

41

9

GC,RTX+CYC,Bel,CYC,AZA

IV+V (7/4)

2,245

Prednisone 5 mg per day (13 months since RB)

Pt 2

F/W

24

5

GC,MMF,RTX + CYC

V (6/5)

3,012

Prednisone 7.5 mg per day (14 months since RB)

Pt 3

F/W

61

8

GC,RTX,CYC (high doses)

IV+V (8/5)

2,855

Prednisone 5 mg per day (13 months since RB)

Pt 4

F/W

20

10

MMF,RTX,CyA,Bel

III+V (7/4)

1,925

Prednisone 5 mg per day (14 months since RB)

Pt 5

F/W

54

20

GC,MMF,IgG iv,Bel

IV (7/4)

2,345

Prednisone 5 mg per day (13 months since RB)

  1. Bel, belimumab; iv, intravenous; AZA, azathioprine, RTX, rituximab, MMF, mycophenolate mofetil, GC, glucocorticoids, CYC, cyclophosphamide, CyA, cyclosporine.
  2. aSex (male/female) and gender (man/woman) of participants was determined based on self-report.
  3. bAll patients underwent a kidney biopsy within 2 months before starting daratumumab.
  4. cActivity (A) and chronicity (C) scores.
  5. dTime (months) since renal biopsy in brackets. RB, renal biopsy.
Back to article page